- Home
- RQI vs IMCR Comparison
RQI vs IMCR Comparison
Compare RQI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- IMCR
- Stock Information
- Founded
- RQI 2002
- IMCR 2008
- Country
- RQI United States
- IMCR United Kingdom
- Employees
- RQI N/A
- IMCR N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RQI Finance
- IMCR Health Care
- Exchange
- RQI Nasdaq
- IMCR Nasdaq
- Market Cap
- RQI 1.7B
- IMCR 1.8B
- IPO Year
- RQI N/A
- IMCR 2021
- Fundamental
- Price
- RQI $12.49
- IMCR $33.42
- Analyst Decision
- RQI
- IMCR Buy
- Analyst Count
- RQI 0
- IMCR 9
- Target Price
- RQI N/A
- IMCR $57.00
- AVG Volume (30 Days)
- RQI 432.6K
- IMCR 280.0K
- Earning Date
- RQI 01-01-0001
- IMCR 11-05-2025
- Dividend Yield
- RQI 8.20%
- IMCR N/A
- EPS Growth
- RQI N/A
- IMCR N/A
- EPS
- RQI N/A
- IMCR N/A
- Revenue
- RQI N/A
- IMCR $356,145,000.00
- Revenue This Year
- RQI N/A
- IMCR $29.67
- Revenue Next Year
- RQI N/A
- IMCR $11.12
- P/E Ratio
- RQI N/A
- IMCR N/A
- Revenue Growth
- RQI N/A
- IMCR 26.78
- 52 Week Low
- RQI $9.17
- IMCR $23.15
- 52 Week High
- RQI $12.64
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- RQI 50.69
- IMCR 44.21
- Support Level
- RQI $12.41
- IMCR $35.33
- Resistance Level
- RQI $12.67
- IMCR $36.76
- Average True Range (ATR)
- RQI 0.14
- IMCR 1.57
- MACD
- RQI -0.01
- IMCR -0.20
- Stochastic Oscillator
- RQI 40.48
- IMCR 24.65
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.